Back to news

Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Globe Newswire•16/11/2026•07:01 ET
3

Key Highlights

  • ➤PEMGARDA Q3 net product revenue $15.4 million, up 18% year over year
  • ➤Q3 net loss $33.5 million versus $10.5 million a year earlier
  • ➤DECLARATION Phase 3 VYD2311 interim data expected imminently after FDA dialogue
  • ➤LIBERTY Phase 3 showed VYD2311 superior safety and tolerability versus an mRNA vaccine
  • ➤Cash and equivalents totaled $126.4 million at September 30, 2026

Expert Statements

Marc Elia, Chairman and Chief Executive Officer of Invivyd

“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”

Marc Elia, Chairman and Chief Executive Officer of Invivyd

“While our DECLARATION data readout timing has been updated as we continued to work with regulators and policymakers on immunization regulation in America broadly, we are pleased that U.S. regulators understand the important role monoclonal antibodies can play in infectious disease going forward.”

Marc Elia, Chairman and Chief Executive Officer of Invivyd

“We look forward to providing DECLARATION data and a regulatory update imminently, and we appreciate investor patience as we endeavor to set the stage for anticipated rapid advancement should VYD2311 DECLARATION data demonstrate an attractive clinical profile.”

Bill Duke, Chief Financial Officer of Invivyd

“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”

Bill Duke, Chief Financial Officer of Invivyd

“With a bolus of REVOLUTION clinical program spend in the rear view at this time, we look forward to a new posture of increased operating efficiency while we work to bring VYD2311 to vulnerable Americans as fast as possible.”

* DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communicated * Updated data timing driven by dialogue between Invivyd and the U.S. FDA 1) to refine details on the Accelerated Approval approach for VYD2311, and 2) to expand the accelerated regulatory approach and enable rapid development of future Invivyd monoclonal antibodies, including Invivyd’s measles antibody candidate; further update to be provided with DECLARATION interim analysis data * Achieved Q3 2026 PEMGARDA(®) (pemivibart) net product revenue of $15.4 million, representing 18% growth versus Q3 2025 net product revenue of $13.1 million * Appointed Chairman Marc W. Elia as Chief Executive Officer * Announced positive topline results from LIBERTY Phase 3 clinical trial, which demonstrated VYD2311 safety and tolerability superior to an mRNA-based COVID-19 vaccine and lack of interference with vaccine-induced neutralizing antibody titers * Announced initiation of FLINTLOCK Phase 2 clinical trial of VYD2311, which will evaluate VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injury * Investments being made in commercial preparedness for VYD2311; Invivyd plans to host a Medical and Commercial Investor Event in 1H 2027 to describe commercial plans and early expressions of institutional demand * Q3 2026 ending cash and cash equivalents of $126.4 million NEW HAVEN, Conn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in